Indication
In combination with palbociclib and fulvestrant for the treatment of adult patients with PIK3CA‑mutated, oestrogen receptor (ER)‑positive, HER2‑negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment.
Medicine details
- Medicine name:
- inavolisib (Itovebi)
- SMC ID:
- SMC2902
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 12 October 2026
- SMC meeting date:
- 01 September 2026
- Patient group submission deadline:
- 06 July 2026